Research programme: gene therapies - Audentes Therapeutics

Drug Profile

Research programme: gene therapies - Audentes Therapeutics

Alternative Names: AAV-CASQ2 gene therapy - Audentes; AAV-MTM1 (AT001); AT 132; AT 307; AT 342; AT 982; AT-001 - Audentes/REGENXBIO; AT-002 - Audentes/REGENXBIO; AT-003 - Audentes/REGENXBIO; XLMTM gene therapy (AT001) - Audentes/Genethon

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Audentes Therapeutics; Genethon
  • Developer Audentes Therapeutics; Genethon; University of Pennsylvania
  • Class Gene therapies
  • Mechanism of Action Alpha glucosidase expression stimulants; Gene transference; Myotubularin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Musculoskeletal disorders
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Glycogen storage disease type II; Hyperbilirubinaemia; Musculoskeletal disorders; Ventricular tachycardia

Most Recent Events

  • 06 Feb 2017 US FDA approves IND application for AT 342 in Hyperbilirubinaemia
  • 01 Feb 2017 Audentes plans a phase I/II trial for Hyperbilirubinaemia
  • 12 Nov 2016 Audented Therapeutics plans to file an IND application with the US FDA for Glycogen storage disease type II in the fourth quarter of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top